HAEMONETICS CORP 8-K

What Happened
Haemonetics Corporation announced it repaid in full at maturity its outstanding 0.00% Convertible Senior Notes due 2026 on March 2, 2026. The company paid an aggregate $300,000,000 in cash to retire the notes.

Key Details

• $300,000,000 paid in cash to retire the outstanding principal of the Notes.
• Notes: 0.00% Convertible Senior Notes due 2026; repayment occurred at maturity on March 2, 2026.
• Funding: repayment was made with cash on hand and borrowings under the company’s revolving credit facility.
• No holders exercised conversion rights prior to the close of business on the second scheduled trading day immediately preceding maturity; associated capped call transactions expired upon maturity.

Why It Matters
This removes the company’s outstanding convertible note liability and prevents the potential equity dilution that would have resulted if holders had converted their notes. However, the repayment used both cash and borrowings under the revolving credit facility, which affects near-term liquidity and borrowing levels. The expiration of the capped call transactions means related hedges/options tied to the notes are no longer in effect.